samedan logo
 
 
 
spacer
home > ebr > winter 2002 > crossbreeding and commercial consolidation in the uppsala biotech cluster
PUBLICATIONS
European Biopharmaceutical Review

Crossbreeding and Commercial Consolidation in the Uppsala Biotech Cluster

The Uppsala region has undergone a remarkable transformation in the biomedical area since the mid-1990s. The city, which lies about 70 kilometres north of the Swedish capital Stockholm, has seen a virtual explosion of research projects, business initiatives, entrepreneurial activity, new companies and industrial investment in the biotechnology and life science sectors.

Tradition, cutting edge research, access to human and financial capital, as well as a growing global market demanding solutions relying on biotech research and development, has created what has become known as the 'Uppsala Phenomenon'. "Today there are about 140 life science companies in Uppsala, of which more than 50 are biotech companies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Per Odebrant, Freelance Science and Business Journalist
Per Odebrant is a Swedish freelance journalist specialising in science and business issues. He has a particular focus on applications of biotechnology, information technology and materials science. He also writes on matters concerning management, industrial organisation and intellectual capital. Per contributes to various national dailies, national and international magazines, and trade journals. He has also been a Consultant Project Manager to the Swedish Government's Information Technology Commission.
Per holds a degree in Philosophy/Linguistics from the University of Lund and has authored three novels. He was commissioned to write this article by STUNS, the Foundation for Collaboration between the Universities in Uppsala, the Business Community and Society.

spacer
Per Odebrant
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Eurofins BioPharma Product Testing Columbia supports Plus Therapeutics’ Key RNLTM Development and cGMP Drug Manufacturing

COLUMBIA, Missouri, May 12, 2021 – Eurofins BioPharma Product Testing Columbia (the “Company”), part of the largest network of harmonized bio/pharmaceutical GMP product testing laboratories worldwide, today announced a collaboration agreement with Plus Therapeutics, Inc. (“Plus Therapeutics”).
More info >>

White Papers

Life Cycle of an Analytical Method - a Case Study on the Monocyte Activation Test

Wickham Laboratories Limited

Pyrogens, a heterogeneous group of fever inducing contaminants, are comprised of microbial and non-microbial compounds; e.g. endotoxin (lipopolysaccharide, LPS) produced by Gram-negative bacteria, lipoteichoic acid (LTA) from Gram-positive bacteria, bacterial DNA (CpG-motive), endogenous pyrogens, virus and fungi particles or even fragments of packaging materials, plastic and dust. Contaminat ion wi th pyrogens in pharmaceutical products, biotherapeutics and on medical devices can lead to life threatening fever reactions. To ensure consumer safety, pyrogen testing is mandatory for parenteral products and medical devices.
More info >>

 
Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement